4.4 Review

Osteoporosis and fractures in rheumatoid arthritis

期刊

CURRENT OPINION IN RHEUMATOLOGY
卷 33, 期 3, 页码 270-276

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0000000000000789

关键词

bone mineral density; osteoporosis; rheumatoid arthritis

资金

  1. Department of Veteran's Affairs
  2. Rheumatology Research Foundation Scientist Development Award
  3. VA Clinical Science Research & Development Merit Awards [CX001703, CX001514]
  4. VA Clinical Science Research & Development Merit Award [CX001703]
  5. VA Clinical Trial Merit Review Award [CX001514]

向作者/读者索取更多资源

RA patients have increased risk for osteoporotic fracture. Factors such as ACPA positivity, glucocorticoid use, poor functional status, and frailty contribute to low BMD and fractures. Tight disease control and biologic therapies may help mitigate fracture risk.
Purpose of review Rheumatoid arthritis (RA) is associated with increased risk for osteoporotic fracture. We highlight RA-specific risk factors for bone mineral density (BMD) loss and fractures and considerations regarding the diagnosis and treatment of osteoporosis in patients with RA. Recent findings Anticitrullinated protein antibody (ACPA) positivity, although associated with low BMD in early RA, is not associated with accelerated BMD loss over time when compared to ACPA negative individuals. Studies have found reduced BMD in individuals on low doses of glucocorticoids (GCs). Poor functional status and frailty are additional important risk factors for low BMD and fractures. Heightened fracture risk in RA may be mitigated by tight disease control, and biologic therapies are associated with more stable BMD compared to nonbiologic therapies. Evidence-based guidelines specific for treating osteoporosis in patients with RA do not exist. Thus, treatment decisions are based on general osteoporosis guidelines, taking into account additional RA-specific risk factors. Recent studies have advanced knowledge of RA-specific risk factors for BMD loss and fractures. Future studies applying these findings to modify established fracture risk algorithms as well as evaluating osteoporosis treatments in RA cohorts are needed to reduce the risk of disabling fractures in these patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据